Dr. Fang Wu obtained PhD degree from the Department of Biochemistry, University of Zurich (UZH) in 2007. He became a postdoctoral scientist in the Department of Organic Chemistry, University of Basel and in the Brain Mind Institute, Swiss Federal Institute of Technology (EPFL) during 2008-2010. He starts to carry out his independent research at the Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University since 2011.
His current research focuses on the development of new drug leads targeting enzymes and studying their underlying mechanism in the related diseases (ysl.sjtu.edu.cn). He has identified several novel inhibitors for enzyme targets involved in various diseases, e.g. cancer, neurodegenerative diseases by using novel high-throughput bioassays, and uncovers few underlying mechanisms for drug resistance and the regulation of amyloid beta generation with the pharmacological probes. The research work has been published in FASEB J, Chemical Communications, J. Med. Chem., Cell Death and Disease, ACS Chemical Biology, JBC or ChemBioChem. Dr. Fang Wu is currently serving as an Editorial Board Member of Chemical Biology field for Scientific Reports.
Title : New indications for FDA-approved drugs: Selective inhibition of the growth of Helicobacter pylori by covalent allosteric regulation of urease